The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 1 study of REGN1400 (anti-ErbB3) combined with erlotinib or cetuximab in patients (pts) with advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck cancer (SCCHN).
Kyriakos P. Papadopoulos
Research Funding - Regeneron
Alex A. Adjei
Research Funding - Regeneron
Drew Warren Rasco
Research Funding - Regeneron
Liming Liu
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Richard J. Kao
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Carrie M. Brownstein
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
A Thomas DiCioccio
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Israel Lowy
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Pamela Trail
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Ding Wang
Research Funding - Regeneron